{"id":974684,"date":"2026-06-23T08:21:00","date_gmt":"2026-06-23T12:21:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/"},"modified":"2026-06-23T08:21:00","modified_gmt":"2026-06-23T12:21:00","slug":"silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/","title":{"rendered":"Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial"},"content":{"rendered":"
\n

\n
\n Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program<\/i>
\n <\/b>\n <\/p>\n

SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) — Silo Pharma (Nasdaq: SILO) (\u201cSilo\u201d or \u201cthe Company\u201d), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has confirmed the physical, chemical and microbiological stability of its investigational soft-mist intranasal prophylactic, SPC-15, through nine months of real-time testing. The stability data demonstrates that SPC-15\u2019s formulation maintains physical, chemical, and microbiological integrity over nine months at long term and six months at accelerated conditions.<\/p>\n

The stability program was conducted under long-term and accelerated storage conditions aligned
with requirements for investigational new drug (IND)-enabling chemistry, manufacturing, and controls (CMC) documentation. Data showed that SPC-15\u2019s formulation and device remained within predefined specifications for assay, impurities, pH, and microbiological quality through nine months, and the product remained in trend for predefined key device spray performance tests. Six-month accelerated stability data was consistent and aligned with long term data.<\/p>\n

\u201cThe positive stability data support continued advancement of our IND-enabling development program and contribute to the manufacturing information required in an IND submission for a first-in-human Phase 1 clinical study,\u201d said Eric Weisblum, CEO of Silo Pharma. \u201cThis important milestone validates our adherence to current Good Manufacturing Practice (cGMP) standards.\u201d<\/p>\n

\n About SPC-15<\/b>\n <\/p>\n

SPC-15\u00a0is an investigational intranasal serotonin 5-HT4 receptor agonist\u00a0being developed by Silo Pharma for\u00a0stress-induced psychiatric conditions, primarily\u00a0post-traumatic stress disorder (PTSD)\u00a0and anxiety, using a special\u00a0soft mist nasal spray\u00a0delivery system for fast brain action. It’s in preclinical stages, partnering with Columbia University, and aims for an accelerated FDA approval pathway (505(b)(2)) by leveraging biomarkers and novel delivery<\/p>\n

\n About Silo Pharma, Inc.<\/b>
\n
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company\u2019s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer\u2019s disease. Silo\u2019s research is conducted in collaboration with leading universities and laboratories.\u00a0silopharma.com<\/a><\/p>\n

\n Forward Looking Statements<\/b>
\n
This news release contains \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words \u201ccould\u201d, \u201cbelieve\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201ccontinue\u201d, \u201cpredict\u201d, \u201cpotential\u201d, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company\u2019s technology platforms, retaining and expanding the Company\u2019s customer base, fluctuations in consumer spending on the Company\u2019s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.<\/p>\n

\n Contact<\/b>
\n
(800) 705-0120
investors@silopharma.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) — Silo Pharma (Nasdaq: SILO) (\u201cSilo\u201d or \u201cthe Company\u201d), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has confirmed the physical, chemical and microbiological stability of its investigational soft-mist intranasal prophylactic, SPC-15, through nine months of real-time testing. The stability data demonstrates that SPC-15\u2019s formulation maintains physical, chemical, and microbiological integrity over nine months at long term and six months at accelerated conditions. The stability program was conducted under long-term and accelerated storage conditions alignedwith requirements for investigational new drug (IND)-enabling chemistry, manufacturing, and controls (CMC) documentation. Data showed that … <\/p>\n

Continue reading “Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-974684","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSilo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) — Silo Pharma (Nasdaq: SILO) (\u201cSilo\u201d or \u201cthe Company\u201d), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has confirmed the physical, chemical and microbiological stability of its investigational soft-mist intranasal prophylactic, SPC-15, through nine months of real-time testing. The stability data demonstrates that SPC-15\u2019s formulation maintains physical, chemical, and microbiological integrity over nine months at long term and six months at accelerated conditions. The stability program was conducted under long-term and accelerated storage conditions alignedwith requirements for investigational new drug (IND)-enabling chemistry, manufacturing, and controls (CMC) documentation. Data showed that … Continue reading "Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-23T12:21:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDg0OSM3NjczMTI3IzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial\",\"datePublished\":\"2026-06-23T12:21:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\\\/\"},\"wordCount\":585,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MDg0OSM3NjczMTI3IzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\\\/\",\"name\":\"Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MDg0OSM3NjczMTI3IzUwMDA2OTMzOQ==\",\"datePublished\":\"2026-06-23T12:21:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MDg0OSM3NjczMTI3IzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MDg0OSM3NjczMTI3IzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial - Market Newsdesk","og_description":"Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) — Silo Pharma (Nasdaq: SILO) (\u201cSilo\u201d or \u201cthe Company\u201d), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has confirmed the physical, chemical and microbiological stability of its investigational soft-mist intranasal prophylactic, SPC-15, through nine months of real-time testing. The stability data demonstrates that SPC-15\u2019s formulation maintains physical, chemical, and microbiological integrity over nine months at long term and six months at accelerated conditions. The stability program was conducted under long-term and accelerated storage conditions alignedwith requirements for investigational new drug (IND)-enabling chemistry, manufacturing, and controls (CMC) documentation. Data showed that … Continue reading \"Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-23T12:21:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDg0OSM3NjczMTI3IzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial","datePublished":"2026-06-23T12:21:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/"},"wordCount":585,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDg0OSM3NjczMTI3IzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/","name":"Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDg0OSM3NjczMTI3IzUwMDA2OTMzOQ==","datePublished":"2026-06-23T12:21:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDg0OSM3NjczMTI3IzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDg0OSM3NjczMTI3IzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-reports-positive-stability-data-for-spc-15-ptsd-treatment-advancing-program-toward-first-in-human-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/974684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=974684"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/974684\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=974684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=974684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=974684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}